ImmunityBio, Inc.
For the period ended Dec 31, 2025. Filed Feb 23, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 23, 2026
IBRX$6.75-5.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Financial Statements and Supplementary Data
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
| Page | |
|---|---|
| Reports of Independent Registered Public Accounting Firm (PCAOB ID: 34) | 161 |
| Report of Independent Registered Public Accounting Firm (PCAOB ID: 42) | 163 |
| Consolidated Balance Sheets as of December 31, 2025 and 2024 | 164 |
| Consolidated Statements of Operations for the years ended December 31, 2025, 2024 and 2023 | 166 |
| Consolidated Statements of Comprehensive Loss for the years ended December 31, 2025, 2024 and 2023 | 167 |
| Consolidated Statements of Stockholders’ Deficit for the years ended December 31, 2025, 2024 and 2023 | 168 |
| Consolidated Statements of Cash Flows for the years ended December 31, 2025, 2024 and 2023 | 171 |
| Notes to Consolidated Financial Statements | 174 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.